Valuation
- Market cap
- 637,668,000
- Revenue TTM
- $183,880,000
- Net income TTM
- $-83,500,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- -45.41%
- Debt to equity
- 0.55
Trading
- Volume
- 3,762,989
- Avg volume
- 13,243,056
- Day's range
- $0.97 – $1.00
- Shares out
- 644,239,000
- Stochastic %K
- 43%
- Beta
- 0.62
- Analysts
- Moderate Buy
- Price target
- $3.00
Company profile
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplasti...
Show more
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 650 473 7700
- Website
- https://www.geron.com
- Address
- 919 East Hillsdale Boulevard, Suite 250, Foster City, United States
Latest news
No headlines yet.
